TCGA-95-7944-01A-11R-2187-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.560
- INTERFERON_GAMMA_RESPONSE+0.550
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.340
- COMPLEMENT+0.310
- COAGULATION+0.280
- MYC_TARGETS_V2+0.260
- APICAL_SURFACE+0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
Top 10 suppressed
- NOTCH_SIGNALING-0.460
- PROTEIN_SECRETION-0.440
- PEROXISOME-0.390
- CHOLESTEROL_HOMEOSTASIS-0.380
- FATTY_ACID_METABOLISM-0.380
- MTORC1_SIGNALING-0.370
- HEDGEHOG_SIGNALING-0.350
- OXIDATIVE_PHOSPHORYLATION-0.330
- ANDROGEN_RESPONSE-0.320
- MITOTIC_SPINDLE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-AAR3-01A-11R-A41B-07 | — | cohortA1 | 0.894 |
| 2 | TCGA-90-A59Q-01A-11R-A26W-07 | — | cohortA1 | 0.874 |
| 3 | SRR934966 | — | — | 0.863 |
| 4 | SRR934910 | — | — | 0.856 |
| 5 | SRR603658 | GTEX | — | 0.839 |
| 6 | SRR1402239 | GTEX | — | 0.834 |
| 7 | MNG64 | — | — | 0.829 |
| 8 | SRR1335446 | GTEX | — | 0.824 |
| 9 | SRR1369219 | GTEX | — | 0.818 |
| 10 | TCGA-22-1005-01A-01R-0692-07 | — | cohortMD2 | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |